{"title":"生姜散通过NLRP3/Caspase-1通路改善MCAO诱导的大鼠细胞焦亡和炎症","authors":"Lulu Qin , Lilin Peng , Yifan Sun , Guixian Chen , Chenghao Du , Ruizhi Xie , Ying Ling , Haoyou Xu , Min Zhao , Yuanqi Zhao , Zequan Zheng","doi":"10.1016/j.jstrokecerebrovasdis.2025.108314","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>This study aims to explore the effects and mechanisms of Shengjiang Powder (SJP) in alleviating ischemic stroke.</div></div><div><h3>Methods</h3><div>The middle cerebral artery occlusion and reperfusion (MCAO) model was established in rats for both the model and medication groups. Neurological function scores, TTC staining, Hematoxylin-Eosin staining and Nissl staining were employed to evaluate the preventive and therapeutic effects of SJP on MCAO in rats. Real-time quantitative polymerase chain reaction, western blotting, and immunofluorescence double staining were used to detect the expression levels of biological markers related to the NLRP3/Caspase-1 pathway.</div></div><div><h3>Results</h3><div>SJP demonstrated an improvement in brain tissue damage in rats subjected to MCAO. SJP inhibited the activation of the NLRP3/Caspase-1 pathway after MCAO in rats. Caspase-1 was primarily expressed in neurons and microglia 24 h post-MCAO in rats, with minimal expression in astrocytes.</div></div><div><h3>Conclusion</h3><div>SJP ameliorates brain tissue damage by inhibiting the activation of the NLRP3/Caspase-1 pathway, thereby reducing the inflammatory response and cell pyroptosis induced by MCAO in rats.</div></div>","PeriodicalId":54368,"journal":{"name":"Journal of Stroke & Cerebrovascular Diseases","volume":"34 7","pages":"Article 108314"},"PeriodicalIF":1.8000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Shengjiang powder ameliorates cell pyroptosis and inflammation induced by MCAO in rats through the NLRP3/Caspase-1 pathway\",\"authors\":\"Lulu Qin , Lilin Peng , Yifan Sun , Guixian Chen , Chenghao Du , Ruizhi Xie , Ying Ling , Haoyou Xu , Min Zhao , Yuanqi Zhao , Zequan Zheng\",\"doi\":\"10.1016/j.jstrokecerebrovasdis.2025.108314\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>This study aims to explore the effects and mechanisms of Shengjiang Powder (SJP) in alleviating ischemic stroke.</div></div><div><h3>Methods</h3><div>The middle cerebral artery occlusion and reperfusion (MCAO) model was established in rats for both the model and medication groups. Neurological function scores, TTC staining, Hematoxylin-Eosin staining and Nissl staining were employed to evaluate the preventive and therapeutic effects of SJP on MCAO in rats. Real-time quantitative polymerase chain reaction, western blotting, and immunofluorescence double staining were used to detect the expression levels of biological markers related to the NLRP3/Caspase-1 pathway.</div></div><div><h3>Results</h3><div>SJP demonstrated an improvement in brain tissue damage in rats subjected to MCAO. SJP inhibited the activation of the NLRP3/Caspase-1 pathway after MCAO in rats. Caspase-1 was primarily expressed in neurons and microglia 24 h post-MCAO in rats, with minimal expression in astrocytes.</div></div><div><h3>Conclusion</h3><div>SJP ameliorates brain tissue damage by inhibiting the activation of the NLRP3/Caspase-1 pathway, thereby reducing the inflammatory response and cell pyroptosis induced by MCAO in rats.</div></div>\",\"PeriodicalId\":54368,\"journal\":{\"name\":\"Journal of Stroke & Cerebrovascular Diseases\",\"volume\":\"34 7\",\"pages\":\"Article 108314\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Stroke & Cerebrovascular Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S105230572500093X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stroke & Cerebrovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S105230572500093X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Shengjiang powder ameliorates cell pyroptosis and inflammation induced by MCAO in rats through the NLRP3/Caspase-1 pathway
Background
This study aims to explore the effects and mechanisms of Shengjiang Powder (SJP) in alleviating ischemic stroke.
Methods
The middle cerebral artery occlusion and reperfusion (MCAO) model was established in rats for both the model and medication groups. Neurological function scores, TTC staining, Hematoxylin-Eosin staining and Nissl staining were employed to evaluate the preventive and therapeutic effects of SJP on MCAO in rats. Real-time quantitative polymerase chain reaction, western blotting, and immunofluorescence double staining were used to detect the expression levels of biological markers related to the NLRP3/Caspase-1 pathway.
Results
SJP demonstrated an improvement in brain tissue damage in rats subjected to MCAO. SJP inhibited the activation of the NLRP3/Caspase-1 pathway after MCAO in rats. Caspase-1 was primarily expressed in neurons and microglia 24 h post-MCAO in rats, with minimal expression in astrocytes.
Conclusion
SJP ameliorates brain tissue damage by inhibiting the activation of the NLRP3/Caspase-1 pathway, thereby reducing the inflammatory response and cell pyroptosis induced by MCAO in rats.
期刊介绍:
The Journal of Stroke & Cerebrovascular Diseases publishes original papers on basic and clinical science related to the fields of stroke and cerebrovascular diseases. The Journal also features review articles, controversies, methods and technical notes, selected case reports and other original articles of special nature. Its editorial mission is to focus on prevention and repair of cerebrovascular disease. Clinical papers emphasize medical and surgical aspects of stroke, clinical trials and design, epidemiology, stroke care delivery systems and outcomes, imaging sciences and rehabilitation of stroke. The Journal will be of special interest to specialists involved in caring for patients with cerebrovascular disease, including neurologists, neurosurgeons and cardiologists.